Live feed08:45:00·28dPRReleasevia QuantisnowA single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemiaByQuantisnow·Wall Street's wire, on your screen.LLY· Eli Lilly and CompanyHealth Care
